Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Therapix Biosciences

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): THX-160

            Therapeutic Area: Neurology Product Name: THX-160

            Highest Development Status: Preclinical Product Type: Small molecule

            Recipient: The University of Calgary

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 02, 2020

            Details:

            This collaboration is expected to facilitate the further development of THX-160 for the treatment of pain, following efficacy pre-clinical studies that demonstrated the analgesic advantages of THX-160 over control.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tetrahydrocannabinol,Palmitoylethanolamide

            Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Evero

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership May 19, 2020

            Details:

            As part of the joint venture, Therapix transferred to Evero its THX-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset purchase agreement.